📊 CVS Key Takeaways
Is CVS HEALTH Corp (CVS) a Good Investment?
CVS demonstrates concerning fundamental deterioration with revenue growth of 7.8% failing to translate into earnings expansion (net income flat YoY) and EPS declining sharply 62%, indicating severe margin compression and/or shareholder dilution. Weak liquidity metrics (current ratio 0.87x, quick ratio 0.66x) combined with poor capital efficiency (ROE 3.8%, ROA 1.2%) and high debt burden ($60.5B) relative to profitability suggest the business is struggling to create shareholder value despite scale.
CVS Health shows solid scale and resilient top-line growth, supported by meaningful operating cash flow and positive free cash flow generation. However, the quality of that growth is weakened by extremely thin margins, flat net income, and a sharp decline in diluted EPS, while below-1.0 liquidity ratios limit flexibility. Fundamentally, the business appears stable but not strong enough to justify a more bullish view until profitability improves.
CVS HEALTH Corp Key Strengths (CVS)
- Positive revenue growth of 7.8% YoY demonstrates continued market demand
- Positive free cash flow generation of $3.4B provides debt servicing capacity
- Adequate interest coverage ratio of 6.5x indicates debt is manageable at current levels
- Revenue growth of 7.8% YoY at very large scale indicates durable demand across the business
- Operating cash flow of $10.64B and free cash flow of $7.81B provide internal funding capacity
- Leverage appears manageable with debt/equity of 0.85x and interest coverage of 6.5x
CVS Stock Risks: CVS HEALTH Corp Investment Risks
- Severe margin compression: 7.8% revenue growth producing 0.0% net income growth signals deteriorating profitability
- Alarming liquidity position with current ratio 0.87x and quick ratio 0.66x indicating potential short-term payment challenges
- Historically poor capital returns (ROE 3.8%, ROA 1.2%) and 62% EPS decline suggest structural business challenges and significant shareholder dilution
- High leverage with $60.5B long-term debt limits financial flexibility despite manageable 0.78x debt-to-equity ratio
- Profitability is very weak, with 5.3% gross margin, 1.2% operating margin, and 0.4% net margin
- Diluted EPS fell 62.0% YoY, signaling pressure on earnings quality despite revenue growth
- Liquidity is tight with a 0.84x current ratio and 0.63x quick ratio
Key Metrics to Watch
- Net profit margin trend - must expand or show stabilization to justify hold
- Operating cash flow sustainability - declining trend would signal business deterioration
- Current and quick ratios - must improve above 1.0x and 0.8x respectively for financial health
- EPS trajectory - must stabilize and turn positive YoY to demonstrate improving shareholder value
- Operating margin and net margin trend
- Diluted EPS recovery versus revenue growth
CVS HEALTH Corp (CVS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 3.4% FCF margin may limit capital allocation flexibility. The current ratio below 1.0x warrants monitoring of short-term liquidity.
CVS Profit Margin, ROE & Profitability Analysis
CVS vs Consumer Sector: How CVS HEALTH Corp Compares
How CVS HEALTH Corp compares to Consumer sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CVS HEALTH Corp Stock Overvalued? CVS Valuation Analysis 2026
Based on fundamental analysis, CVS HEALTH Corp shows some fundamental concerns relative to the Consumer sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CVS HEALTH Corp Balance Sheet: CVS Debt, Cash & Liquidity
CVS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: CVS HEALTH Corp's revenue has grown significantly by 38% over the 5-year period, indicating strong business expansion. The most recent EPS of $6.47 reflects profitable operations.
CVS Revenue Growth, EPS Growth & YoY Performance
CVS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $94.6B | $1.8B | $1.41 |
| Q3 2025 | $95.4B | $87.0M | $0.07 |
| Q2 2025 | $91.2B | $1.0B | $0.80 |
| Q1 2025 | $88.4B | $1.1B | $0.88 |
| Q3 2024 | $89.8B | $87.0M | $0.07 |
| Q2 2024 | $88.9B | $1.8B | $1.41 |
| Q1 2024 | $85.3B | $1.1B | $0.88 |
| Q3 2023 | $81.2B | $2.0B | $1.49 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CVS HEALTH Corp Dividends, Buybacks & Capital Allocation
CVS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CVS HEALTH Corp (CIK: 0000064803)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CVS
What is the AI rating for CVS?
CVS HEALTH Corp (CVS) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CVS's key strengths?
Claude: Positive revenue growth of 7.8% YoY demonstrates continued market demand. Positive free cash flow generation of $3.4B provides debt servicing capacity. ChatGPT: Revenue growth of 7.8% YoY at very large scale indicates durable demand across the business. Operating cash flow of $10.64B and free cash flow of $7.81B provide internal funding capacity.
What are the risks of investing in CVS?
Claude: Severe margin compression: 7.8% revenue growth producing 0.0% net income growth signals deteriorating profitability. Alarming liquidity position with current ratio 0.87x and quick ratio 0.66x indicating potential short-term payment challenges. ChatGPT: Profitability is very weak, with 5.3% gross margin, 1.2% operating margin, and 0.4% net margin. Diluted EPS fell 62.0% YoY, signaling pressure on earnings quality despite revenue growth.
What is CVS's revenue and growth?
CVS HEALTH Corp reported revenue of $100.4B.
Does CVS pay dividends?
CVS HEALTH Corp pays dividends, with $847.0M distributed to shareholders in the trailing twelve months.
Where can I find CVS SEC filings?
Official SEC filings for CVS HEALTH Corp (CIK: 0000064803) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CVS's EPS?
CVS HEALTH Corp has a diluted EPS of $2.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CVS's fundamental grade?
Based on our AI fundamental analysis in June 2026, CVS HEALTH Corp has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CVS stock overvalued or undervalued?
Valuation metrics for CVS: ROE of 3.8% (sector avg: 18%), net margin of 2.9% (sector avg: 8%). Compare these metrics with sector averages to assess valuation.
What is CVS's AI grade for 2026?
Our dual AI analysis gives CVS HEALTH Corp a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CVS's free cash flow?
CVS HEALTH Corp's operating cash flow is $4.2B, with capital expenditures of $849.0M. FCF margin is 3.4%.
How does CVS compare to other Consumer stocks?
Vs Consumer sector averages: Net margin 2.9% (avg: 8%), ROE 3.8% (avg: 18%), current ratio 0.87 (avg: 1.5).